Skip to content
Screener

Absci Corporation ABSI Stock-Based Comp

Stock-Based Comp at other companies

Schrodinger logo
SchrodingerSDGR
$8.79M-17.2%
Recursion Pharmaceuticals, Inc. logo
Recursion Pharmaceuticals, Inc.RXRX
$19.5M-25.5%
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
$12.81M+44.6%
AbCellera Biologics Inc. logo
AbCellera Biologics Inc.ABCL
$12.29M-13.5%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$14.22M+55.0%
Assembly Biosciences logo
Assembly BiosciencesASMB
$1.12M+56.7%

Segments

By segment

See full
Segment One$4.38M-11.4%

Other financials

Income statement

See full
Revenue$215.0K-81.8%
Operating income-$30.8M-11.2%
Net income-$29.6M-12.3%
EPS (diluted)-$0.19+9.5%

Balance sheet

See full
Cash & equivalents$9.7M-84.9%
Total debt$4.0M-37.2%
Total equity$172.0M-13.5%
Total assets$195.6M-15.9%

Cash flow

See full
Operating cash flow-$26.3M-20.5%
CapEx$30.0K+20.0%
Free cash flow-$26.3M-20.5%

Valuation

See full
Market cap$1.41B+235%
Enterprise value$1.4B+279%
P/S765.8×+664×

Profitability

See full
Operating margin-6,723%-14,525pp
Net margin-6,450.8%-13,699pp
FCF margin-5,365.2%-9,300pp

Returns & leverage

See full
Return on equity-63.9%+28.0pp
Debt / equity0.0×
Current ratio6.6×+0.9×

Where this comes from

Reported directly by Absci Corporation in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The source filing: Absci Corporation’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:24 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001672688-26-000088
(In thousands)For the Three Months Ended March 31, 2026For the Three Months Ended March 31, 2025
Net loss$(29,599)$(26,346)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization2,7283,072
Stock-based compensation4,3804,913
Accretion of discount on marketable securities(421)(699)
Other(267)7
Accounts receivable, net(1,384)
Prepaid expenses and other current assets(862)924

Item 1. Unaudited Condensed Consolidated Financial Statements

FAQ

What is Absci Corporation's stock-based comp?
Absci Corporation (ABSI) reported stock-based comp of $4.38M in Q1 2026.
How has Absci Corporation's stock-based comp changed year-over-year?
Absci Corporation's stock-based comp decreased by 10.8% year-over-year, from $4.91M to $4.38M.
What is the long-term trend for Absci Corporation's stock-based comp?
Over 4 years (2021 to 2025), Absci Corporation's stock-based comp has grown at a 14.6% compound annual growth rate (CAGR), from $10.61M to $18.32M.
What does stock-based comp mean?
Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Ask your AI about Absci Corporation's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude